Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open Label, Randomised, Controlled Trial of Ipilimumab and Nivolumab With Concurrent Intracranial Stereotactic Radiotherapy Versus Ipilimumab and Nivolumab Alone in Patients With Melanoma Brain Metastases.

NCT03340129 is registered in ClinicalTrials.gov with Melanoma Institute Australia as lead sponsor.

NCT NCT03340129
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03340129 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open Label, Randomised, Controlled Trial of Ipilimumab and Nivolumab With Concurrent Intracranial Stereotactic Radiotherapy Versus Ipilimumab and Nivolumab Alone in Patients With Melanoma Brain Metastases.
Lead sponsor
Melanoma Institute Australia
Phase
Phase 2
Overall status
Recruiting
Start date
August 14, 2019
Completion date
August 31, 2029
Enrollment
218 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma stage iv